Miguel Ángel
Hernández Pérez
Profesor Asociado Asistencial
Montreal Neurological Institute and Hospital
Montreal, CanadáPublicaciones en colaboración con investigadores/as de Montreal Neurological Institute and Hospital (1)
2018
-
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
The Lancet Neurology, Vol. 17, Núm. 5, pp. 405-415